A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.
Clinical trial NCT07264673 · RECRUITING
Trial details
- NCT number
- NCT07264673
- Sponsor
- Fondazione Ricerca Traslazionale
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-17
- Primary completion
- 2027-10-01
- Enrollment
- 160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.